Few Exits, But Lots Of Cash: Third Rock Closes $516M Third Fund
This article was originally published in Start Up
Executive Summary
The early-stage biotech venture firm drew its largest fund yet, topping $1 billion raised since inception, despite notching only two exits from its first two funds.
You may also be interested in...
Shire Adds To HGT Unit With Lotus Acquisition; Gets Preclinical Rare Disease Treatment
Shire makes a bolt-on acquisition that will complement both its rare disease franchise and its regenerative medicines unit.
Genentech, Constellation Enter Largest Epigenetics Tie-Up Yet
For $95 million guaranteed, Genentech gains rights to broad research in the emerging field over a three-year period, as well as an option to acquire the start-up outright.
Lotus Tissue Repair Scores $26 Million in Series A Round
Rare disease start-up scores Series A financing and technology patents to develop a treatment for a deadly genetic disorder.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports